Towards Healthcare
503A U.S. Compounding Pharmacies Market Size Envisioned at USD 7.18 Bn by 2032

503A U.S. Compounding Pharmacies Market Size Envisioned at USD 7.18 Bn by 2032

The report covers 503A U.S. Compounding Pharmacies Market is segmented by Products such as oral, liquid preparations, topical, rectal, ophthalmic, nasal and otic. Sterility classifies sterile and non-sterile compounds. Therapeutic areas encompass hormone replacement, pain management, dermatology, pediatrics, urology and other specialized fields. End-users include oral administration, hospitals and clinics, specialty clinics and other healthcare settings. The report offers the value (in USD Billion) for the above segments.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global 503A U.S. Compounding Pharmacies Market Assessment

  • Overview
  • Global 503A U.S. Compounding Pharmacies Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Oral
    • Liquid Preparations
    • Topical
    • Rectal
    • Ophthalmic
    • Nasal
    • Otic
  • Global 503A U.S. Compounding Pharmacies Market Size Value (US$) and Volume (Billion Tons), by Sterility (2021 – 2033)
    • Sterile
    • Non-Sterile
  • Global 503A U.S. Compounding Pharmacies Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Area (2021 – 2033)
    • Hormone replacement 
    • Pain management
    • Dermatology 
    • Pediatrics 
    • Urology 
    • Others
  • Global 503A U.S. Compounding Pharmacies Market Size Value (US$) and Volume (Billion Tons), by End-User (2021 – 2033)
    • Oral 
    • Hospitals and Clinics 
    • Specialty Clinics 
    • Other
  • Global 503A U.S. Compounding Pharmacies Market Size Value (US$) and Volume (Billion Tons), by State (2021 – 2033)
    • Florida 
    • California 
    • Chicago 
    • New Jersey
    • Pennsylvania
    • Rest of the U.S

Company Profiles

  • Triangle Compounding
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Fagron
  • B. Braun SE
  • Pencol Specialty Pharmacy
  • Vertisis Custom Pharmacy
  • Optum Inc
  • Pavilion Compounding Pharmacy, LLC.
  • Village Compounding Pharmacy
  • McGuff Compounding Pharmacy
  • Wedgewood Pharmacy

Conclusion & Recommendations

  • Insight Code: 5070
  • No. of Pages: 150
  • Format: PDF/PPT/Excel
  • Published: October 2023
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

503A compounding pharmacies can prepare a wide range of medications, including sterile and non-sterile formulations, customized dosages, and various delivery forms such as creams, injections, capsules, and more. They often cater to patients with specific medication needs, allergies, or sensitivities.

Compounded medications may or may not be covered by insurance plans. Coverage depends on the individual insurance policy and the specific compounded medication. Patients should consult their insurance providers to determine coverage.

Alliance for Pharmacy Compounding, National Library of Medicine, and United States Government Accountability Office

The key difference lies in regulatory oversight. 503A compounding pharmacies operate under state pharmacy boards regulations and can compound customized medications for individual patient prescriptions. In contrast, 503B outsourcing facilities are subject to more stringent federal regulations by the FDA, allowing them to produce larger quantities of compounded medications without patient-specific prescriptions for healthcare facilities.

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 509

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 509